Olaparib is a clinically used PARP1-i chemotherapeutic agent that is especially effective for treatments of BRCA1 or BRCA2 negative cancers, such as ovarian and breast cancer types [30,31,32]. The gene discussed is BRCA1; the disease is cancer.